GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Acarix AB (OSTO:ACARIX) » Definitions » EV-to-EBITDA

Acarix AB (OSTO:ACARIX) EV-to-EBITDA : -3.71 (As of May. 21, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Acarix AB EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Acarix AB's enterprise value is kr193.13 Mil. Acarix AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was kr-52.10 Mil. Therefore, Acarix AB's EV-to-EBITDA for today is -3.71.

The historical rank and industry rank for Acarix AB's EV-to-EBITDA or its related term are showing as below:

OSTO:ACARIX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -8.22   Med: -1.72   Max: 0.7
Current: -3.61

During the past 10 years, the highest EV-to-EBITDA of Acarix AB was 0.70. The lowest was -8.22. And the median was -1.72.

OSTO:ACARIX's EV-to-EBITDA is ranked worse than
100% of 487 companies
in the Medical Devices & Instruments industry
Industry Median: 16.36 vs OSTO:ACARIX: -3.61

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-21), Acarix AB's stock price is kr0.3245. Acarix AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was kr-0.090. Therefore, Acarix AB's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Acarix AB EV-to-EBITDA Historical Data

The historical data trend for Acarix AB's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acarix AB EV-to-EBITDA Chart

Acarix AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.31 -2.75 -4.23 -0.89 -1.46

Acarix AB Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.89 -2.31 -2.14 -1.46 -

Competitive Comparison of Acarix AB's EV-to-EBITDA

For the Medical Devices subindustry, Acarix AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acarix AB's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Acarix AB's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Acarix AB's EV-to-EBITDA falls into.



Acarix AB EV-to-EBITDA Calculation

Acarix AB's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=193.132/-52.099
=-3.71

Acarix AB's current Enterprise Value is kr193.13 Mil.
Acarix AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-52.10 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Acarix AB  (OSTO:ACARIX) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Acarix AB's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.3245/-0.090
=At Loss

Acarix AB's share price for today is kr0.3245.
Acarix AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.090.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Acarix AB EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Acarix AB's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Acarix AB (OSTO:ACARIX) Business Description

Traded in Other Exchanges
Address
World Trade Center Malmo, Jungmansgatan 12, Malmo, SWE, 211 19
Acarix AB is a Swedish medical technology company that develops innovative solutions for rapid AI-based exclusion of coronary artery disease (CAD). The CE-marked CADScor System, which has also received DeNovo approval from the FDA, is intended for patients experiencing chest pain with suspected coronary artery disease and is designed to help reduce millions of cases of unnecessary, invasive, and costly diagnostics. The CADScor System uses advanced acoustics and AI technology to non-invasively rule out CAD in less than 10 minutes, with at least 96% certainty.

Acarix AB (OSTO:ACARIX) Headlines

No Headlines